AMITRIPTYLINE TO TREAT PAINFUL BLADDER SYNDROME

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。间质性膀胱炎是一种慢性、疼痛的膀胱壁炎性疾病，由Hunner博士于1914年首次描述。自20世纪80年代中期以来，NIDDK/NIH、间质性膀胱炎协会和新闻界的努力使这种疾病从默默无闻变得突出，联邦和私人花费了数亿美元寻找治疗方法。尽管作出了这些努力，但对这种疾病的了解仍然很少，特征也不清楚，治疗大多是经验性的，不能令人满意。疼痛性膀胱综合征（PBS），由国际尿失禁协会定义，是“与膀胱充盈相关的耻骨上疼痛的主诉，伴有其他症状，如白天和夜间频率增加，没有证实的尿路感染或其他明显的病理。虽然与间质性膀胱炎（IC）重叠，但PBS是基于患者症状的疾病临床描述，而不依赖于尿动力学或膀胱镜检查结果。该方案将比较口服阿米替林在“新诊断”、“未接受过治疗”的PBS患者与匹配的安慰剂中的疗效、安全性和耐受性，所有患者均接受标准教育/行为矫正计划。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interstital cystitis is a chronic, painful inflammatory condition of the bladder wall first characterized in 1914 by Dr. Hunner. Efforts by the NIDDK/NIH, the Interstitial Cystitis Association and the lay press since the mid-1980's brought the disorder from obscurity to prominence with hundreds of millions of federal and private dollars spent in search for a cure. Despite these efforts, the disease is still poorly understood, poorly characterized, and treatment is mostly empirical and unsatisfactory. Painful bladder syndrome (PBS), as defined by the International Continence Society, is "the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms, such as increased day-time and night-time frequency, in the absence of proven urinary infection or other obvious pathology." Although overlapping with interstitial cystitis (IC), PBS is a clinical description of disease based on the patient's symptoms, and does not depend on urodynamic or cystoscopic findings. This protocol will compare the efficacy, safety and tolerability of oral amitriptyline in "newly diagnosed", "treatment naive" PBS patients with matching placebo, all receiving a standard education/behavioral modification program.